<ul><li>Mastek stock has corrected ~7% and 23% in the last one and three months, trading at a P/E of 18x and 15x FY26/27E EPS.</li><li>NHS England is a major client for Mastek, contributing ~22% of its revenue.</li><li>Mastek's management is closely monitoring the changes in NHS England but does not anticipate a major impact on spending.</li><li>Short-term uncertainty and delays may occur due to the merger activities.</li></ul>

'Add' Mastek Shares Maintains HDFC Securities, Sees Multiple Growth Triggers Ahead

Discover more